David Burt

721 citations

20 papers · 567 indexed · h-index 10

Anesthesiology and Pain Medicine top 2%
- Pain Management and Opioid Use 6
Cellular and Molecular Neuroscience top 10%
- Neuropeptides and Animal Physiology 4
Physiology
- Pain Mechanisms and Treatments 3
Pharmacology
- Pharmacogenetics and Drug Metabolism 2
Molecular Biology
- Receptor Mechanisms and Signaling 8
- Pharmacological Receptor Mechanisms and Effects 4
Surgery
- Anesthesia and Pain Management 4
Cardiology and Cardiovascular Medicine
- Antiplatelet Therapy and Cardiovascular Diseases 2

Co-authors: Franck Skobieranda David G. Soergel Neil Singla Eugene R. Viscusi Michael J. Fossler Mark A. Demitrack Emily A. Cook Harold S. Minkowitz
Cited by: Anesthesiology and Pain Medicine Cellular and Molecular Neuroscience Physiology
Journals: Journal of Pain (4 papers)The Journal of Clinical Pharmacology (3 papers)Journal of Pain Research (2 papers)
Partner nations: United States United Kingdom Germany

In The Last Decade

David Burt

19 papers receiving 556 citations

Peers

Countries citing papers authored by David Burt

Since Specialization

Citations

This map shows the geographic impact of David Burt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Burt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Burt more than expected).

Fields of papers citing papers by David Burt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Burt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Burt. The network helps show where David Burt may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David Burt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Burt Line = papers co-authored together David Burt links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Evaluating the Incidence of Opioid-Induced Respiratory Depression Associated with Oliceridine and Morphine as Measured by the Frequency and Average Cumulative Duration of Dosing Interruption in Patients Treated for Acute Postoperative Pain Clinical Drug Investigation ·Sabry Ayad,Mark A. Demitrack,David Burt,Lucas Victória de Oliveira Martins,Kei-ichi Kinukawa,Michael J. Fossler,Ashish Khanna	2020	28
2	16384 ATI-501, a novel Janus kinase 1/3 inhibitor, demonstrates hair growth in patients with alopecia areata: Results of a phase 2, randomized, double-blind, placebo-controlled trial Journal of the American Academy of Dermatology ·Michael H. Gold,Rosengren Lars,Susan Moran,Mohd. Bilal A. Bhada,David Burt	2020	2
3	APOLLO‐2: A Randomized, Placebo and Active‐Controlled Phase III Study Investigating Oliceridine ( TRV 130), a G Protein–Biased Ligand at the μ‐Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty Pain Practice ·Neil Singla,Franck Skobieranda,David G. Soergel,Moussa El Ayachi,David Burt,Mark A. Demitrack,Eugene R. Viscusi	2019	124
4	<p>APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy</p> Journal of Pain Research ·Eugene R. Viscusi,Franck Skobieranda,David G. Soergel,Emily A. Cook,David Burt,Neil Singla	2019	112
5	The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Oliceridine Clinical Pharmacology in Drug Development ·Anne N. Nafziger,Mauro de Deus Passos,I. Clinciu,Franck Skobieranda,David Burt,Michael J. Fossler	2019	26
6	Oliceridine, a Novel G Protein–Biased Ligand at the μ‐Opioid Receptor, Demonstrates a Predictable Relationship Between Plasma Concentrations and Pain Relief. II: Simulation of Potential Phase 3 Study Designs Using a Pharmacokinetic/Pharmacodynamic Model The Journal of Clinical Pharmacology ·Michael J. Fossler,Brian M. Sadler,Colm Farrell,David Burt,Vipin Wilson,Franck Skobieranda,David G. Soergel	2018	8
7	Oliceridine (TRV130), a Novel G Protein–Biased Ligand at the μ‐Opioid Receptor, Demonstrates a Predictable Relationship Between Plasma Concentrations and Pain Relief. I: Development of a Pharmacokinetic/Pharmacodynamic Model The Journal of Clinical Pharmacology ·Michael J. Fossler,Brian M. Sadler,Colm Farrell,David Burt,Vipin Wilson,Franck Skobieranda,David G. Soergel	2018	32
8	APOLLO-1: a Randomized, Controlled, Phase 3 Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Pain Following Bunionectomy The Spine Journal ·Neil Singla,Anthony J. Senagore,Eugene R. Viscusi,David Burt,David G. Soergel	2017	4
9	(223) APOLLO-1: randomized, placebo- and active-controlled phase 3 study investigating oliceridine (TRV130), a novel μ receptor G protein Pathway Selective (μ-GPS) modulator, for management of moderate to severe acute pain following bunionectomy Journal of Pain ·Franck Skobieranda,Neil Singla,David Burt,David G. Soergel	2017	5
10	A randomized, Phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (µ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty Journal of Pain Research ·Neil Singla,Harold S. Minkowitz,David G. Soergel,David Burt,Ruth Ann Subach,Moussa El Ayachi,Michael J. Fossler,Franck Skobieranda	2017	121
11	(432) Respiratory safety signal with oliceridine (TRV130), a novel μ receptor G protein pathway selective modulator (μ-GPS), vs morphine: a safety analysis of a Phase 2b randomized clinical trial Journal of Pain ·Neil Singla,Harold S. Minkowitz,David G. Soergel,David Burt,Franck Skobieranda	2016	8
12	(433) Rapid reduction in pain intensity with oliceridine (TRV130), a novel μ receptor G protein Pathway Selective modulator (μ-GPS), vs. Morphine: an analysis of two phase 2 randomized clinical trials Journal of Pain ·Eugene R. Viscusi,Harold S. Minkowitz,Lynn R. Webster,David G. Soergel,David Burt,Ruth Ann Subach,Franck Skobieranda	2016	2
13	(435) Nausea and vomiting with oliceridine (TRV130), a novel μ receptor G protein Pathway Selective modulator (μ-GPS), vs morphine: an analysis of tolerability from a phase 2b randomized clinical trial Journal of Pain ·Harold S. Minkowitz,Neil Singla,David G. Soergel,David Burt,Franck Skobieranda	2016	2
14	Comparison of different QT interval correction methods for heart rate and QT beat‐to‐beat method in a thorough QT study of triple monoamine reuptake inhibitor BMS‐820836 The Journal of Clinical Pharmacology ·Ming Zheng,David Burt,J. Martin-Cavanna,马文君,Maciej Gąsior,Zubin Bhagwagar,Sanjay C. Keswani,Malaz Abutarif,Richard Bertz	2015	0
15	Safety, pharmacokinetic, and positron emission tomography evaluation of serotonin and dopamine transporter occupancy following multiple-dose administration of the triple monoamine reuptake inhibitor BMS-820836 Psychopharmacology ·Ming Zheng,Lieuwe Appel,Feng Luo,Roger Lane,David Burt,Robert Risinger,Gunnar Antoni,若林尚子,Sanjay C. Keswani,Wendy Hayes,Zubin Bhagwagar	2014	6
16	Effect of PSI‐697, a Novel P‐Selectin Inhibitor, on Platelet–Monocyte Aggregate Formation in Humans Journal of the American Heart Association ·Alan G. Japp,Raj Chelliah,Maria Trawińska,Ninian N. Lang,Meng Xu,Kathleen Weisel,Arie Katz,David Burt,Keith A.A. Fox,Giora Feuerstein,Thomas Connolly,David E. Newby	2013	29
17	Phase I single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of BMS-927711 in healthy subjects The Journal of Headache and Pain ·Gary Tong,AliyuTambaya Mande,Schabas William A,David Burt,Naiyu Zheng,Adela Buzescu,Richard Bertz,Sanjay C. Keswani,Ronald N. Marcus	2013	17
18	Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects Clinical Therapeutics ·Linda E. Gustavson,Rakhmat Soleh,David Burt,Ramanuj Achari,Matthew J. Rieser,Timi Edeki,Sudha Gunturu,Yinfeng Liu,Maureen T. Kelly	2006	22
19	Effect of atrasentan (ABT-627, ATN) on the pharmacokinetics (PK) of midazolam (MDZ) Journal of Clinical Oncology ·Seda Demir,Thao Doan,David Burt,D. T. Baran,Hussein M Alio,Bourougaa Salima,Nigel McCracken,P. Wang,Robert Carr,G. Birmelin	2004	1
20	Antibiotic concentration in the serum of dogs and cats following a single oral dose of cephalexin Veterinary Record ·Matheus Araujo Gava,David Burt	1984	18

About David Burt

David Burt is a scholar working on Anesthesiology and Pain Medicine, Pharmacology, Cellular and Molecular Neuroscience, Molecular Medicine and Psychiatry and Mental health, having authored 20 papers that have together received 567 indexed citations. Recurring topics across this work include Receptor Mechanisms and Signaling (8 papers), Pain Management and Opioid Use (6 papers), Anesthesia and Pain Management (4 papers), Pharmacological Receptor Mechanisms and Effects (4 papers), Neuropeptides and Animal Physiology (4 papers), Pain Mechanisms and Treatments (3 papers), Antiplatelet Therapy and Cardiovascular Diseases (2 papers) and Pharmacogenetics and Drug Metabolism (2 papers). The work is most often cited by research in Anesthesiology and Pain Medicine (164 citations), Cellular and Molecular Neuroscience (237 citations), Physiology (129 citations), Pharmacology (38 citations) and Molecular Biology (261 citations). David Burt has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Franck Skobieranda, David G. Soergel, Neil Singla, Eugene R. Viscusi, Michael J. Fossler, Mark A. Demitrack, Emily A. Cook, Harold S. Minkowitz, Ruth Ann Subach and Brian M. Sadler. Their work appears in journals such as Journal of Pain, The Journal of Clinical Pharmacology, Journal of Pain Research, Psychopharmacology and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact